Skip to search formSkip to main contentSkip to account menu

ReoPro

National Institutes of Health

Related topics

Related topics

3 relations
5 ML abciximab 2 MG/ML Injection [ReoPro]abciximab Injection [ReoPro]

Broader (1)

abciximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: Results from TARGET (do tirofiban and reopro give similar efficacy trial?)
Background: Saphenous vein graft (SVG) percutaneous coronary intervention (PCI) carries a high risk of ischemic complications… 
Highly Cited
2004
Highly Cited
2004
Strategies for the Management of Intraprocedural Thromboembolic Complications with Abciximab (ReoPro)
OBJECTIVE:Most complications related to endovascular neurointerventional procedures are thromboembolic. The objective of this… 
2003
2003
Marginal transfer of ReoPro (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro.
ReoPro (Abciximab), a Fab fragment of a human-murine chimeric monoclonal antibody, binds to glycoprotein IIb/IIIa receptors on… 
Highly Cited
2002
Highly Cited
2002
Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial
Background—The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists… 
Review
2001
Review
2001
Platelet Aggregation Inhibition with Glycoprotein IIb–IIIa Inhibitors
Inhibitors of the platelet receptor glycoprotein (GP) IIb–IIIa are a novel and potent class of antithrombotic drugs for the… 
Highly Cited
1999
Highly Cited
1999
Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women.
UNLABELLED The monoclonal antibody fragment c7E3 Fab (ReoPro), by binding to platelet surface fibrinogen receptors (glycoprotein… 
1999
1999
Combined use of orgaran and reopro during coronary angioplasty in patients unable to receive heparin
Orgaran, a heparinoid, has been used successfully in patients with heparin‐induced thrombocytopenia. We report three cases in… 
1999
1999
Cardioprotective effects of abciximab (ReoPro) in an isolated perfused rat heart model of ischemia and reperfusion.
Ischemia followed by reperfusion in the presence of polymorphonuclear leukocytes (PMNs) results in cardiac contractile… 
Highly Cited
1998
Highly Cited
1998
Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and αvβ3 Integrins
Background—Large, randomized, and blinded clinical trials (EPIC, EPILOG, and CAPTURE) have demonstrated that abciximab (ReoPro… 
1997
1997
Angioscopic evaluation of site-specific administration of ReoPro.
Systemic administration of newer antiplatelet agents such as the GP IIb/IIIa agent ReoPro (Centocor BV Leiden, The Netherlands… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)